Traveler’s diarrhea - Pipeline Insight, 2021
This report can be delivered to the clients within 24 Hours
DelveInsight’s, “Traveler’s diarrhea - Pipeline Insight, 2021,” report provides comprehensive insights about 6+ companies and 7+ pipeline drugs in Traveler’s diarrhea pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Traveler’s diarrhea: Overview
Traveler’s diarrhea (TD) is a digestive tract disorder. Classic Traveler’s diarrhea is defined as three or more loose bowel actions with at least one of the following accompanying symptoms: nausea, vomiting, abdominal cramps or pain, fever or blood in the stools. Travelers' diarrhea usually is caused by eating food contaminated with bacteria or, less commonly, with parasites or viruses. Diarrhea usually is mild, self-limited, and resolves spontaneously. The first line of treatment for Traveler’s diarrhea will often be home remedies and over-the-counter (OTC) treatments to resolve mild cases of the illness. Anti-motility agents provide symptomatic relief and are useful therapy in TD. Antibiotics are effective in reducing the duration of diarrhea by about a day in cases caused by bacterial pathogens that are susceptible to the particular antibiotic prescribed.
'Traveler’s diarrhea - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Traveler’s diarrhea pipeline landscape is provided which includes the disease overview and Traveler’s diarrhea treatment guidelines. The assessment part of the report embraces, in depth Traveler’s diarrhea commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Traveler’s diarrhea collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Traveler’s diarrhea report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Traveler’s diarrhea Emerging Drugs
Further product details are provided in the report..
Traveler’s diarrhea: Therapeutic Assessment
This segment of the report provides insights about the different Traveler’s diarrhea drugs segregated based on following parameters that define the scope of the report, such as:
Traveler’s diarrhea: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Traveler’s diarrhea therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Traveler’s diarrhea drugs.
Traveler’s diarrhea Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Traveler’s diarrhea - Pipeline Insight, 2021,” report provides comprehensive insights about 6+ companies and 7+ pipeline drugs in Traveler’s diarrhea pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Traveler’s diarrhea: Overview
Traveler’s diarrhea (TD) is a digestive tract disorder. Classic Traveler’s diarrhea is defined as three or more loose bowel actions with at least one of the following accompanying symptoms: nausea, vomiting, abdominal cramps or pain, fever or blood in the stools. Travelers' diarrhea usually is caused by eating food contaminated with bacteria or, less commonly, with parasites or viruses. Diarrhea usually is mild, self-limited, and resolves spontaneously. The first line of treatment for Traveler’s diarrhea will often be home remedies and over-the-counter (OTC) treatments to resolve mild cases of the illness. Anti-motility agents provide symptomatic relief and are useful therapy in TD. Antibiotics are effective in reducing the duration of diarrhea by about a day in cases caused by bacterial pathogens that are susceptible to the particular antibiotic prescribed.
'Traveler’s diarrhea - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Traveler’s diarrhea pipeline landscape is provided which includes the disease overview and Traveler’s diarrhea treatment guidelines. The assessment part of the report embraces, in depth Traveler’s diarrhea commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Traveler’s diarrhea collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Traveler’s diarrhea R&D. The therapies under development are focused on novel approaches to treat/improve Traveler’s diarrhea.
This segment of the Traveler’s diarrhea report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Traveler’s diarrhea Emerging Drugs
- IMM 124E: Immuron
- LMN-101: Lumen Bioscience
Further product details are provided in the report..
Traveler’s diarrhea: Therapeutic Assessment
This segment of the report provides insights about the different Traveler’s diarrhea drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Traveler’s diarrhea
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Traveler’s diarrhea: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Traveler’s diarrhea therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Traveler’s diarrhea drugs.
Traveler’s diarrhea Report Insights
- Traveler’s diarrhea Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Traveler’s diarrhea drugs?
- How many Traveler’s diarrhea drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Traveler’s diarrhea?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Traveler’s diarrhea therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Traveler’s diarrhea and their status?
- What are the key designations that have been granted to the emerging drugs?
- Nippon Shinyaku
- Immuron
- Eveliqure Biotechnologies
- Lumen Bioscience
- Scandinavian Biopharma
- Sigmoid Pharma Limited
- Prulifloxacin
- IMM 124E
- Campylobacter jejuni/Escherichia coli oral vaccine
- Escherichia coli/Shigella oral vaccine
- LMN-101
- Traveller's diarrhoea vaccine
- Oral vaccines
Introduction
Executive Summary
Traveler’s diarrhea: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Traveler’s diarrhea – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Traveler’s diarrhea companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Traveler’s diarrhea Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
IMM 124E: Immuron
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Mid Stage Products (Phase II)
Comparative Analysis
Campylobacter jejuni/Escherichia coli oral vaccine: Immuron
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Early Stage Products (Phase I)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Preclinical/Discovery Stage Products
Comparative Analysis
Escherichia coli/Shigella oral vaccine: Eveliqure Biotechnologies
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Inactive Products
Comparative Analysis
Traveler’s diarrhea Key Companies
Traveler’s diarrhea Key Products
Traveler’s diarrhea- Unmet Needs
Traveler’s diarrhea- Market Drivers and Barriers
Traveler’s diarrhea- Future Perspectives and Conclusion
Traveler’s diarrhea Analyst Views
Traveler’s diarrhea Key Companies
Appendix
Executive Summary
Traveler’s diarrhea: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Traveler’s diarrhea – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Traveler’s diarrhea companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Traveler’s diarrhea Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
IMM 124E: Immuron
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Mid Stage Products (Phase II)
Comparative Analysis
Campylobacter jejuni/Escherichia coli oral vaccine: Immuron
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Early Stage Products (Phase I)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Preclinical/Discovery Stage Products
Comparative Analysis
Escherichia coli/Shigella oral vaccine: Eveliqure Biotechnologies
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Inactive Products
Comparative Analysis
Traveler’s diarrhea Key Companies
Traveler’s diarrhea Key Products
Traveler’s diarrhea- Unmet Needs
Traveler’s diarrhea- Market Drivers and Barriers
Traveler’s diarrhea- Future Perspectives and Conclusion
Traveler’s diarrhea Analyst Views
Traveler’s diarrhea Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Traveler’s diarrhea
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Traveler’s diarrhea
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Traveler’s diarrhea
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Traveler’s diarrhea
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
